Estrogenic Agent (noncontraceptive) Patents (Class 514/874)
-
Patent number: 8784878Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: GrantFiled: December 11, 2012Date of Patent: July 22, 2014Assignee: Acrux DDS Pty Ltc.Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Traci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 8604047Abstract: Methods and compositions are described for the treatment of very severe acne vulgaris, including nodulocystic acne and conglobate acne. Compounds which inhibit either or both type 1 and type 2 isoforms of steroid 5?-reductase are administered daily in either oral or topical formulations to patients suffering from severe forms of acne vulgaris. Very high dosages of such compounds can effectively be administered oral just once a week and be successful.Type: GrantFiled: August 10, 2010Date of Patent: December 10, 2013Assignee: Elorac, Inc.Inventor: Joel E. Bernstein
-
Patent number: 8530446Abstract: An oral composition for increasing equol production by inner-intestinal bacteria, wherein such composition contains difructose anhydride as an active ingredient to activate the equol production function of inner-intestinal bacteria.Type: GrantFiled: October 25, 2005Date of Patent: September 10, 2013Assignee: Fancl CorporationInventors: Akiko Tamura, Norihiro Shigematsu, Hiroshi Hara
-
Patent number: 8357393Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: GrantFiled: December 7, 2004Date of Patent: January 22, 2013Assignee: Acrux DDS Pty Ltd.Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Taci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 8026228Abstract: One aspect of the present invention relates to a method of hormone replacement in mammals, which method comprises the oral administration of an estrogenic component and a progestogenic component to a mammal in an effective amount to prevent or treat symptoms of hypoestrogenism, wherein the estrogenic component is selected from the group consisting of substances represented by the above formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; and no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors.Type: GrantFiled: May 23, 2002Date of Patent: September 27, 2011Assignee: Pantarhei Bioscience B.V.Inventors: Herman Jan Tijmen Coelingh Bennink, Evert Johannes Bunschoten, Christian Franz Holinka
-
Patent number: 7923440Abstract: A method of treating or preventing an immune mediated disorder in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula: in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention relates to a pharmaceutical formulation comprising the aforementioned estrogenic component, an immunotherapeutic agent and a pharmaceutically acceptable excipient.Type: GrantFiled: June 11, 2003Date of Patent: April 12, 2011Assignee: Pantarhei Bioscience B.V.Inventors: Evert Johannes Bunschoten, Herman Jan Tijmen Coelingh Bennink, Christian Franz Holinka
-
Patent number: 7858607Abstract: The invention concerns a concentrated hormone pharmaceutical composition having from about 0.6 to about 80% of at least one hormone; from about 20 to about 90.4% of at least one solvent, and optionally a pharmaceutically acceptable carrier. The concentrated hormone pharmaceutical composition according to this invention provides a concentrated pharmaceutical composition that is easy to use and saves time and money to the pharmacies dealing with BHRT pharmaceutical products.Type: GrantFiled: September 22, 2003Date of Patent: December 28, 2010Inventor: Stephen A. Mamchur
-
Patent number: 7772219Abstract: The present invention provides extended cycle contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin. The disclosed extended cycle contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.Type: GrantFiled: May 3, 2004Date of Patent: August 10, 2010Assignee: Teva Women's Health, Inc.Inventors: Carole S. Ben-Maimon, Howard Hait, Kathleen Z. Reape, Lance J. Bronnenkant
-
Patent number: 7053077Abstract: The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of gestagens, preferably continuously in the form of an implant or in the form of an intrauterine releasing system (IUD). Estrone sulfamate, estradiol sulfamate or an N-acyl sulfamate of estrone, estradiol or estriol having up to 7 C-atoms in the acyl chain, or a combination comprised of two or more of said active ingredients are used as biogenic estrogen sulfamates.Type: GrantFiled: May 13, 1999Date of Patent: May 30, 2006Assignee: Schering AGInventors: Walter Elger, Pekka Lähteenmäki, Matti Lehtinen, Gudrun Reddersen, Holger Zimmermann, Michael Oettel, Sigfrid Schwarz
-
Patent number: 7029657Abstract: The present invention relates to an improvement in a method of contraception, in treatment of benign gynecological disorders, and in hormone replacement. The improved method includes administering intranasally an estrogenic compound and an androgenic compound, and in some embodiments an optional progestin compound, in a once-daily bolus formulation comprised of the two or three steroids complexed with a cyclodextrin. An intranasal delivery system for administration of the formulation is also described.Type: GrantFiled: November 15, 2002Date of Patent: April 18, 2006Assignee: Balance Pharmaceuticals, Inc.Inventors: Malcolm C. Pike, Darcy V. Spicer, AnnaMarie Daniels, John R. Daniels
-
Patent number: 7015253Abstract: The present invention provides treatment regimens for treating diseased prostate tissue, including the steps of chemically ablating prostate tissue and coadministering an antiandrogen. In some embodiments, prostate tissue is chemically ablated by injection of ethanol, or an injectable gel comprising ethanol, into prostate tissue. Steroidal and non-steroidal antiandrogens are suitable antiandrogens. One suitable non-steroidal antiandrogen is bicalutamide. The treatment regimen is suitable for treatment of prostate tissue diseases including benign prostatic hyperplasia and prostatic carcinoma. The invention further provides a treatment regimen for treating benign prostatic hyperplasia, including the steps of damaging prostate tissue and coadministering an antiandrogen. Also provided by the present invention is a kit for treating a human male, including a means for necrosing prostate tissue, an antiandrogen drug, and a means for administering the antiandrogen drug.Type: GrantFiled: July 9, 2002Date of Patent: March 21, 2006Assignee: American Medical Systems, Inc.Inventors: M. Alejandro Sousa Escandon, Johann J. Neisz
-
Patent number: 6977250Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.Type: GrantFiled: September 17, 2001Date of Patent: December 20, 2005Assignee: New Life Pharmaceuticals Inc.Inventor: Gustavo C. Rodriguez
-
Patent number: 6960337Abstract: An improvement in a method of treating benign gynecological disorders is described. In the method, treatment of a benign gynecological disorder with a composition comprised of a gonadotropin releasing hormone (GnRH) compound and an estrogenic compound, and optionally, an androgenic compound, is extended to premenopausal women who are not receiving an exogenously supplied progestin on a regular or periodic basis. Treatment in accord with the invention does not increase significantly the risk of endometrial hyperplasia. The method is also suitable for contraception.Type: GrantFiled: November 15, 2002Date of Patent: November 1, 2005Assignee: Balance Pharmaceuticals, Inc.Inventors: Anne-Marie Daniels, John R. Daniels, Malcolm C. Pike, Darcy V. Spicer
-
Patent number: 6958142Abstract: A nasal spray formulation for use in female contraception or in the treatment of benign gynecological disorders is described. The nasal preparation is comprised of a GnRH compound and an estrogenic compound in the form of a water-soluble complex with a water-soluble cyclodextrin. The preparation effectively suppresses ovarian estrogen and progesterone production, and prevents signs and symptoms of estrogen deficiency, without a significant increase in the risk of endometrial hyperplasia.Type: GrantFiled: November 15, 2002Date of Patent: October 25, 2005Assignee: Balance Pharmaceuticals, Inc.Inventors: John R. Daniels, Malcolm C. Pike, Darcy V. Spicer, AnnaMarie Daniels
-
Patent number: 6884440Abstract: Disclosed are a multipurpose, high-functional, alkaline solution composition, preparation therefor and use thereof as a nonspecific immunostimulator. The composition comprises 1-25 parts by weight of borax (Na2B4O7.10H2O), 10?5-10?4 parts by weight of sodium thiosulfate (Na2S2O3.5H2O), 30-150 parts by weight of potassium carbonate, 30-200 parts by weight of refined sugar (C12H22O11), and 100-200 parts by weight of water, based on 100 parts by weight of sodium metasilicate (Na2SiO3.5H2O). In addition to bringing about an improvement in disease resistance, weight gain rate, crop yield, crop quality, harvest time, the composition shows nonspecific immunostimulating activities, including antibody production and immune enhancement, by activating immune cells, thereby maximizing vaccination effects on malignant viral diseases.Type: GrantFiled: April 25, 2003Date of Patent: April 26, 2005Assignee: Barodon-S.F. Corp.Inventors: Soo-Il Choi, Hyun-Suk Choi, Kyung-Soo Jeon, Byung-Woo Yoo, Yong-Ho Park
-
Patent number: 6841548Abstract: The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formula R—SO2—O— at their C3 position wherein R is a R1R2N group wherein R1 and R2 are independent of each other and represent a hydrogen atom, a C1-C5 alkyl radical or, together with the N atom, a polymethylene imino radical containing 4 to 6 C atoms, or a morpholino radical. The preparations according to the invention can be used for hormonal contraception and for hormon replacement therapy (HRT). They exhibit a low hepatic estrogenity.Type: GrantFiled: November 21, 2001Date of Patent: January 11, 2005Assignee: Schering AGInventors: Sigfrid Schwarz, Walter Elger, Christel Siemann, Gudrun Reddersen, Birgitt Schneider, Hans-Joachim Siemann
-
Patent number: 6593369Abstract: Topical application of a prostaglandin directly to the clitoris is effective for enhancing female sexual desire and responsiveness.Type: GrantFiled: June 12, 2001Date of Patent: July 15, 2003Assignee: Vivus, Inc.Inventor: Gary W. Neal
-
Patent number: 6548072Abstract: Organic chick pea extracts are phytoestrogens, if present in an amount such as to provide an estrogenic activity equivalent to at least 1 nM of estradiol. Cosmetic compositions containing organic chick pea extracts are useful in improving the appearance of wrinkled, lined, dry, flaky, aged or photodamaged skin and improving skin thickness, elasticity, flexibility and plumpness.Type: GrantFiled: September 20, 1999Date of Patent: April 15, 2003Assignee: Chesebrough-Pond's USA Co., division of Conopco, Inc.Inventors: Sreekumar Pillai, Uma Santhanam, Marieann Carlomusto, Carol Annette Bosko
-
Patent number: 6518319Abstract: A composition is prepared by extracting phytochemicals from plant matter. This composition is enriched preferably in isoflavones, lignans, saponins, catechins and phenolic acids. Soy is the preferred source of these chemicals; however, other plants may also be used, such as red clover, kudzu, flax, and cocoa. The composition is a dietary supplement for treatment of various cancers, pre- and post-menstrual syndromes, and various other disorders.Type: GrantFiled: May 1, 2002Date of Patent: February 11, 2003Assignee: Archer Daniels Midland CompanyInventors: Mark Empie, Eric Gugger
-
Patent number: 6511986Abstract: This invention provides a method of treating or inhibiting an estrogen receptor positive carcinoma in a mammal in need thereof, which comprises providing said mammal with an effective amount of a combination of a rapamycin and an antiestrogen.Type: GrantFiled: August 6, 2001Date of Patent: January 28, 2003Assignee: WyethInventors: Yixian Zhang, Tammy M. Sadler, Philip Frost, Lee Martin Greenberger
-
Patent number: 6403615Abstract: This invention provides methods which are useful for the inhibition of the various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of formula I:Type: GrantFiled: September 29, 2000Date of Patent: June 11, 2002Assignee: Eli Lilly and CompanyInventor: George Joseph Cullinan
-
Patent number: 6391309Abstract: A composition is prepared by extracting phytochemicals from plant matter to form a dietary supplement for treatment of female symptoms. This composition is enriched preferably with two or more fractions of plant matter, namely: isoflavones, lignans, saponins, sapogenins, catechins and phenolic acids. Soy is the preferred source of these chemicals; however, other plants may also be used, such as wheat, psyllium, rice, oats, red clover, kudzu, alfalfa, flax, and cocoa. The isoflavone may be any in a group including malonyl, acetyl, glucoside, and aglycone. The composition is in a concentrated form to be delivered in an easy to consume dosage, such as a pill, tablet, liquid, capsule, or a food supplement including health bars. Most commonly, these female symptoms are hot flashes, osteoporosis, sleep disorders, menopausal symptoms, vaginal dryness, premenstrual syndrome, or other problems relating to a reduction of sex hormones and to menstruation.Type: GrantFiled: July 13, 2000Date of Patent: May 21, 2002Assignee: Archer Daniesl Midland CompanyInventors: Mark Empie, Eric Gugger
-
Patent number: 6297243Abstract: A pharmaceutical composition comprising a LH antagonist or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier is useful for deferring the onset of menopause.Type: GrantFiled: October 29, 1998Date of Patent: October 2, 2001Assignee: Novo Nordisk A/SInventor: Christian Groendahl
-
Patent number: 6232350Abstract: A preparation for the treatment and/or prevention of dementia disorders, especially disorders due to regressive cellular changes. A close of at least one steroidal antagonist is included as the active agent. A mixture of such substances can also be applied.Type: GrantFiled: May 7, 1997Date of Patent: May 15, 2001Assignee: Altramed Holdings, Ltd.Inventor: Rainer Denecke
-
Patent number: 6228852Abstract: The invention features a physiologically acceptable cream that contains estrogen, progesterone, and testosterone molecules that are identical to the estrogen, progesterone, and testosterone molecules naturally produced by the human body. The cream may be self-administered to the skin and is useful as a means of hormone replacement therapy, which may begin at around the time of menopause.Type: GrantFiled: July 8, 1997Date of Patent: May 8, 2001Inventor: Carolyn V. Shaak
-
Patent number: 6174857Abstract: Pharmaceutical compositions and methods for the treatment of osteoporosis in mammals are disclosed. The compositions are suitable for parenteral administration and comprise Insulin-Like Growth Factor I (IGF-I) and a pharmaceutically acceptable carrier. The compositions for use in the methods may also include bone antiresorptive compounds.Type: GrantFiled: December 30, 1996Date of Patent: January 16, 2001Assignee: Novartis CorporationInventor: Robert Roland B{umlaut over (u)}rk
-
Patent number: 6156786Abstract: This invention provides methods which are useful for the inhibition of the various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of formula I: ##STR1##Type: GrantFiled: November 4, 1998Date of Patent: December 5, 2000Assignee: Eli Lilly and CompanyInventor: George Joseph Cullinan
-
Patent number: 6107346Abstract: The present application relates to a series of compounds, and pharmaceutical formulations thereof, of the formula ##STR1## which provide a method of inhibiting hyperlipidemia, especially hypercholesterolemia, and the pathological sequelae thereof, in mammals, including humans.Type: GrantFiled: August 4, 1998Date of Patent: August 22, 2000Assignee: Eli Lilly and CompanyInventor: George Joseph Cullinan
-
Patent number: 6096301Abstract: Proliferation of breast cancer is treated by a combined type I interferon/non-steroidal antiestrogen therapy. Preferably antiestrogen treatment is sequential to treatment with interferon.Type: GrantFiled: March 8, 1993Date of Patent: August 1, 2000Assignee: Industria Farmaceutica Serono SpAInventors: Sergio Del Bianco, Gigliola Sica
-
Patent number: 6093748Abstract: A method of inhibiting hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a non-steroidal suppressor of angiogenesis.Type: GrantFiled: November 3, 1997Date of Patent: July 25, 2000Inventors: Gurpreet S. Ahluwalia, Peter Styczynski, Douglas Shander
-
Patent number: 6080762Abstract: The present invention relates to formulations and methods for pulmonary and nasal administration of raloxifene.Type: GrantFiled: April 8, 1999Date of Patent: June 27, 2000Assignee: Eli Lilly and CompanyInventors: Darrel LaVern Allen, Ronald Keith Wolff, Paula Ann Leiter, Richard Leon Tielking
-
Patent number: 6060063Abstract: A phytoestrogen supplement and methods of preparation are described. The basis of the oral phytoestrogen supplement was a preparation of the pomegranate material, preferably pomegranate seeds, which were contacted with an appropriate solvent as described below, preferably including water and ethanol. Preferably, the supplement also included an herbal mixture, including schizandra berries and Chinese asparagus root, and most preferably including Chinese licorice root and Chinese angelica root. The phytoestrogen supplement can also be prepared from pomegranate material alone without the addition of other herbals, which involves fermenting the pomegranate material including the pomegranate seeds. The basis of topical phytoestrogen supplements was a mixture of a preparation of the pomegranate material, preferably pomegranate seeds, which were pressed as described below to produce pomegranate oil, and of the coconut milk. Preferably, the supplements also included schizandra berries and Chinese asparagus root.Type: GrantFiled: April 5, 1999Date of Patent: May 9, 2000Inventor: Ephraim Philip Lansky
-
Patent number: 6040333Abstract: The present invention relates to dietary supplements containing low doses of phytoestrogens for supplementing the specific phytochemical dietary needs of perimenopausal and menopausal women.Type: GrantFiled: June 12, 1997Date of Patent: March 21, 2000Assignee: Energetics, Inc.Inventor: Sherry D. Jackson
-
Patent number: 5942539Abstract: Methods of using phytoestrogens, in particular, isoflavones in the prevention and treatment of endometriosis and related disease conditions in females. One method comprises administering a therapeutically effective dosage of a phytoestrogen to females with endometriosis, females having symptoms related to endometriosis, or to females at risk of developing or suffering recurrence of endometriosis. In another method, at least one phytoestrogen may be administered singly or in combination with at least one hormonal therapeutic agent such as GnRH analogs, androgens, progestins, estrogens or any combination thereof. The therapeutically effective dosage of the phytoestrogen or the combination therapeutic ranges between about 25 and about 250 mg/day.Type: GrantFiled: October 3, 1997Date of Patent: August 24, 1999Assignee: Wake Forest UniversityInventors: Claude L. Hughes, Jr., J. Mark Cline, Thomas B. Clarkson, Daniel B. Whitesides
-
Patent number: 5919812Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R2 and R3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia.Type: GrantFiled: March 4, 1997Date of Patent: July 6, 1999Assignee: Novo Nordisk A/SInventors: Niels Korsgaard, Michael Shalmi, Birgitte Hjort Guldhammer
-
Patent number: 5891440Abstract: A phytoestrogen oral supplement and ointment, and methods of preparing the supplement and ointment, are described. The oral phytoestrogen supplement is prepared by extracting pomegranate seeds with an aqueous solvent, and admixing the pomegranate seed extract with an herbal extract containing shizandra berries, Chinese asparagus root, and optionally Chinese licorice root and Chinese angelica root. The phytoestrogen ointment is prepared by pressing pomegranate seeds to obtain a pomegranate seed oil, and mixing the pomegranate seed oil with coconut milk to form the ointment. The phytoestrogen ointment can also contain an ethanolic extract of Chinese asparagus root and schizandra berries.Type: GrantFiled: December 31, 1996Date of Patent: April 6, 1999Inventor: Ephraim Philip Lansky
-
Patent number: 5760046Abstract: The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5.alpha.-reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.Type: GrantFiled: February 14, 1996Date of Patent: June 2, 1998Assignee: Merck & Co., Inc.Inventors: Glenn J. Gormley, Keith D. Kaufman, Elizabeth Stoner, Joanne Waldstreicher
-
Patent number: 5744464Abstract: Antigestagens inhibit prostaglandin synthesis by the uterus and thus can be used to treat symptoms of dysmennhorea.Type: GrantFiled: July 26, 1993Date of Patent: April 28, 1998Assignee: Schering AktiengesellschaftInventors: Walter Elger, Krzysztof Chwalisz, Sybille Beier, Marianne Fahnrich
-
Patent number: 5720977Abstract: Oral water-soluble pharmaceutical compositions containing a therapeutically effective amount of a water-soluble and stable estrogen compound such as estropipate (piperazine estrone sulfate), and at least one water-soluble, pharmaceutically acceptable calcium salt in the presence of a suitable, pharmaceutically acceptable excipient. Compositions which include an organic acid and a calcium carbonate or bicarbonate compound which reacts with the organic acid when the composition is added to water to provide effervescence are preferred.Type: GrantFiled: February 1, 1996Date of Patent: February 24, 1998Inventor: Romano Deghenghi
-
Patent number: 5686437Abstract: Novel derivatives of estrogenic nuclei, contain a side-chain substitution of the formula --R.sup.1 ?B--R.sup.2 --!.sub.x L--G and may be used in pharmaceutical compositions as sex steroid activity inhibitors useful in the treatment of both androgen-related and estrogen-related diseases.Type: GrantFiled: June 7, 1995Date of Patent: November 11, 1997Assignee: Endorecherche Inc.Inventors: Fernand Labrie, Yves Merand
-
Patent number: 5654011Abstract: The present invention relates to dietary supplements for supplementing the dietary needs of women and preventing or reducing life stage associated health risks during each of their principal adult life stages (pre-perimenopause, perimenopause and menopause, or post-menopause).Type: GrantFiled: July 30, 1996Date of Patent: August 5, 1997Assignee: Energetics, Inc.Inventors: Sherry D. Jackson, Jeffrey B. Blumberg
-
Patent number: 5569459Abstract: A composition is disclosed for controlling the stimulation of estrogen production, which comprises:(a) 15 to 120 parts by weight of one or more phytoestrogen compounds calculated as a free aglycon form of isoflavone;(b) up to 75 parts by weight of dried licorice root extract;(c) 10 to 80 parts by weight of a sedative selected from the group consisting of Valerian root dry extract, passion flower dry extract, and Ginseng root powder;(d) up to 50, preferably 10 to 20 parts by weight of beta-carotene;(e) up to 200, preferably 15 to 150 parts by weight of pyridoxine hydrochloride;(f) up to 50, preferably 12 to 30 parts by weight of Vitamin E;(g) up to 600, preferably 100 to 450 parts by weight of calcium contained in a biologically acceptable calcium salt;(h) up to 200, preferably 150 to 250 parts by weight of magnesium contained in a biologically acceptable magnesium salt;(i) up to 100, preferably 10 to 50 parts by weight of zinc contained in a biologically acceptable zinc salt;(j) up to 30 parts by weight of coType: GrantFiled: February 15, 1995Date of Patent: October 29, 1996Assignee: Bio-Virus Research IncorporatedInventor: Mark Shlyankevich
-
Patent number: 5565199Abstract: Systems and methods for synthesizing natural base steroidal hormones and more especially estrogens and progesterone and estrogen-like and progesterone-like compounds and their derivatives which are derived in the form of phytohormones from herbaceous plants and formulated to provide a broad spectrum of estrogenic and/or progesterone activity for influencing physiological processes and biological functions. In particular, phytohormones (i.e. phytoestrogens and/or phytoprogesterone) are synthesized from herbaceous compounds selected from a group consisting of plants having a propensity for simulating estrogenic and/or progesterone hormonal activity that, when entering the bloodstream of a biological organism, either by means of oral ingestion, parenteral injection, or topical application, have a tendency to enhance, supplement and/or maintain estrogen and/or progesterone hormonal levels by means of replacement therapy within a biological organism.Type: GrantFiled: February 7, 1995Date of Patent: October 15, 1996Inventors: Elliot W. Page, Linda G. Rector-Page
-
Patent number: 5547957Abstract: The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5.alpha.-reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.Type: GrantFiled: March 17, 1994Date of Patent: August 20, 1996Assignee: Merck & Co., Inc.Inventors: Glenn J. Gormley, Keith D. Kaufman, Elizabeth Stoner, Joanne Waldstreicher
-
Patent number: 5521214Abstract: A method of inhibiting effects of environmental estrogens comprising administering to a human or other animal in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, -CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: January 25, 1995Date of Patent: May 28, 1996Assignee: Eli Lilly and CompanyInventors: Henry U. Bryant, Jeffrey A. Dodge
-
Patent number: 5424331Abstract: A composition for the treatment or prevention of osteoporosis, is disclosed, which comprises:(a) 75 to 200 parts of one or more phytoestrogen compounds;(b) 0 to 100 parts of dried licorice root extract;(c) 300 to 600 parts of calcium contained in a biologically acceptable calcium salt;(d) 70 to 280 parts of magnesium contained in a biologically acceptable magnesium salt;(e) 4 to 25 parts of zinc contained in a biologically acceptable zinc salt;(f) 5 to 20 parts of beta-carotene;(g) 0.005 to 0.010 parts of Vitamin D as cholecalciferol; and(h) 6 to 12 parts of Vitamin E,in admixture with a biologically acceptable inert carrier. The new compositions are administered to a mammalian subject as either a pharmaceutical or as a dietary supplement.Type: GrantFiled: June 10, 1994Date of Patent: June 13, 1995Assignee: Bio-Virus Research IncorporatedInventor: Mark Shlyankevich
-
Patent number: 5384332Abstract: The present invention provides novel methods of inhibiting aortal smooth muscle cell proliferation, particularly restenosis, in humans, comprising administering to a human in need of treatment an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different provided that, when R.sup.1 and R.sup.2 are the same, each is a methyl or ethyl group, and, when R.sup.1 and R.sup.2 are different, one of them is a methyl or ethyl group and the other is a benzyl group, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 11, 1994Date of Patent: January 24, 1995Assignee: Eli Lilly and CompanyInventor: Steven A. Fontana
-
Patent number: 5364847Abstract: Certain steroidal and non-steroidal compounds have been found to inhibit androgen and estrogen formation. Such inhibition may aid in the reduction of the activity of these hormones and may be useful in the treatment of diseases where, for example, inhibition of androgen or estrogen acitivity is desired. Preferred inhibitors also possess antiestrogenic activity, thus providing the advantage of a double inhibitory action both on estrogen formation and on estrogen action.Type: GrantFiled: October 22, 1992Date of Patent: November 15, 1994Assignee: EndorechercheInventors: Fernand Labrie, Yves Merand
-
Patent number: 5254594Abstract: Remedies for bone diseases comprising, as active ingredient, droloxifene or a salt thereof.Type: GrantFiled: April 8, 1992Date of Patent: October 19, 1993Assignee: Klinge Pharma GmbHInventors: Kazuaki Niikura, Yoshimitsu Nakajima, Yoshitada Notsu, Ryuji Ono, Osamu Nakayama
-
Patent number: 5244668Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.Type: GrantFiled: August 17, 1992Date of Patent: September 14, 1993Assignee: Zetachron, Inc.Inventor: Wallace C. Snipes